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The chloroplast bioreactor is an alternative to fermentation-based systems for production of vaccine anti-
gens and biopharmaceuticals. We report here expression of the plague F1-V fusion antigen in chloroplasts.
Site-specific transgene integration and homoplasmy were confirmed by PCR and Southern blotting. Mature
leaves showed the highest level of transgene expression on the third day of continuous illumination, with a
maximum level of 14.8% of the total soluble protein. Swiss Webster mice were primed with adjuvant-containing
subcutaneous (s.c.) doses of F1-V and then boosted with either adjuvanted s.c. doses (s.c. F1-V mice) or
unadjuvanted oral doses (oral F1-V mice). Oral F1-V mice had higher prechallenge serum immunoglobulin G1
(IgG1) titers than s.c. F1-V mice. The corresponding serum levels of antigen-specific IgG2a and IgA were 2 and
3 orders of magnitude lower, respectively. After vaccination, mice were exposed to an inhaled dose of 1.02 
106 CFU of aerosolized Yersinia pestis CO92 (50% lethal dose, 6.8  104 CFU). All control animals died within
3 days. F1-V given s.c. (with adjuvant) protected 33% of the immunized mice, while 88% of the oral F1-V mice
survived aerosolized Y. pestis challenge. A comparison of splenic Y. pestis CFU counts showed that there was a
7- to 10-log reduction in the mean bacterial burden in survivors. Taken together, these data indicate that oral
booster doses effectively elicit protective immune responses in vivo. In addition, this is the first report of a
plant-derived oral vaccine that protected animals from live Y. pestis challenge, bringing the likelihood of
lower-cost vaccines closer to reality.
The establishment of successful protocols for oral vaccina-
tion could radically alter the current landscape of infectious
diseases. Oral delivery of plant-derived vaccine antigens could
eliminate expensive fermentation and purification systems,
cold storage and transportation steps, and delivery via sterile
needles, significantly reducing costs. Plant-derived oral vac-
cines have other distinct advantages, including the ability to
stimulate both systemic and mucosal immune responses, facil-
itating large-scale production and simplified storage (eliminat-
ing frozen stocks), improving safety due to the lack of human
pathogens or microbial toxin contamination, protecting thera-
peutic proteins by bioencapsulation, and delivering these pro-
teins to the gut-associated lymphoid tissue (7, 15, 80).
The engineering of chloroplasts for the production of vac-
cines and biopharmaceuticals has ushered in a new era in
biotechnology (15, 17, 44). Chloroplast transgenes can express
large amounts of foreign proteins (up to 46% of the total leaf
protein [19]). Transgene silencing does not occur in chloro-
plasts at the levels of transcription and translation (19, 20).
Chloroplasts translate heterologous operons, processed mono-
cistrons, and unprocessed polycistrons (67), enabling the ex-
pression of multivalent vaccines. Most important, chloroplast
transformation offers transgene containment via maternal in-
heritance; expression in leaves or vegetative organs eliminates
transmission of transgenes in reproductive structures (14, 16).
Additional containment methods, such as cytoplasmic male
sterility, have also been developed using the chloroplast ge-
nome (71). Foreign proteins expressed in chloroplasts are pro-
tected in the digestive tract and are efficiently delivered to the
circulatory system (52). Plastid transformation of edible crops,
including soybean, carrot, and lettuce, has been accomplished
recently (22, 45, 49). Moreover, human therapeutic proteins
have been stably expressed in lettuce chloroplasts; oral delivery
of proinsulin expressed in chloroplasts protected nonobese
diabetic mice against the development of insulitis (70). These
advancements have opened the door for developing vaccine
antigens that can be orally administered.
Several vaccine antigens have already been expressed in
chloroplasts, including the cholera toxin B subunit of Vibrio
cholerae (18), Bacillus anthracis protective antigen (47, 87),
LecA from Entamoeba histolytica (11), the 2L21 peptide from
the canine parvovirus (59), and TetC of Clostridium tetani (83).
These antigens were evaluated mostly by using conventional
vaccination strategies, i.e., needle-based subcutaneous (s.c.) or
intraperitoneal delivery. Therefore, further studies are re-
quired to evaluate and understand the mechanism of oral de-
livery of chloroplast-derived vaccine antigens in plant cells.
Yersinia pestis has caused three plague pandemics and killed
approximately 200 million people (62). At least 2,000 cases of
plague are reported annually by the World Health Organization
(http://www.who.int/mediacentre/factsheets/fs267/en/index.html),
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including several recent outbreaks in India. The nonavailability of
a human plague vaccine is a public health concern, given the
potential use of Y. pestis as an agent for bioterrorism (42). Since
the lungs and respiratory tract are vulnerable to a first exposure to
Y. pestis, adequate protective immunity—achieved either by tran-
sudation of high levels of circulating immunoglobulin G (IgG), by
induction of local immunity (IgA), or by a combination of both—
must be available. Indeed, protection against both s.c. (95) and
aerosolized (3, 93) Y. pestis challenges was found to be associated
with F1-V-specific IgG1, a TH2-associated antibody. Systemic
IgG is a known consequence of parenteral immunization, and
many studies have demonstrated the efficacy of s.c. and intramus-
cular vaccines for providing protection against pathogen chal-
lenge (for a review, see reference 94). However, intranasal or
even oral delivery of subunit vaccines may be more effective
because of the ability of such vaccines to elicit protective immu-
nity directly at the mucosal surface.
Human plague vaccines based on either a live, attenuated
strain or a killed, whole-cell preparation (for a review, see
reference 5) are no longer commercially available. Because of
the severity of the infection and the potential of Y. pestis as a
bioterrorist agent, we developed a subunit vaccine produced in
transgenic tobacco chloroplasts. This vaccine offers the advan-
tage of employing two defined antigens that are able to elicit
high-level protection. Of the various Y. pestis antigens that
have been tested preclinically, the fraction 1 (F1) outer cap-
sular and low-calcium response V (LcrV or V) proteins appear
to be the most promising vaccine candidates (9, 31, 64). The F1
protein has been reported to have antiphagocytic capability
(21, 68, 89), while LcrV, a major component of the type III
secretion system, is required for the production and transloca-
tion of Yersinia outer proteins, several of which have antihost
activities in the eukaryotic host cell (63, 77, 79).
Given the high costs associated with needle-based vaccina-
tion, we investigated whether needle-free (i.e., oral) vaccine
delivery could provide animals with similar levels of protection
against pathogen challenge. We hypothesized that a heterolo-
gous prime-boost strategy for plague may provide improved
protection compared with parenteral immunization. We inves-
tigated the efficacy of a plague vaccine protocol that incorpo-
rates both elements of successful vaccination against Y. pestis:
s.c. delivery of enriched antigen preparations of F1-V prepared
from transgenic, low-nicotine tobacco (enF1-V), followed by
oral boosts of antigen expressed in transgenic plants. The ef-
ficacy of the vaccine was assessed by aerosol challenge with Y.
pestis.
However, the intent of this study was not to compare oral
boosters with s.c. boosters (by dosage or number of boosters).
Experimentally, any such comparison is not possible because
oral delivery involves antigens encapsulated in plant cells with-
out any adjuvant, whereas in s.c. delivery antigens bound to an
adjuvant are directly delivered to the circulatory system. It is
not possible to deliver antigens via oral boosters in a quanti-
tative manner because the release of antigens from plant cells
depends on several factors, including the population of bacte-
ria that can degrade the plant cell wall and presentation of an
antigen to the gut-associated lymphoid tissue. It is not possible
to control these factors in experimental animals in a quantita-
tive manner. An equal number of boosters does not guarantee
an equal quantity of antigen delivered. Therefore, this study
simply demonstrated that oral boosting via plant cells is a novel
mode of delivery of vaccine antigens and might provide a
low-cost delivery option, especially for delivery of biodefense
vaccines at times of crisis to a very large population or in
developing countries where cold storage and transportation of
vaccines are major challenges.
MATERIALS AND METHODS
Construction of pLDS-F1V and regeneration of transgenic lines. The F1-V
fusion gene in a pET-24 vector (pPW731, obtained from the United States Army
Medical Research Institute of Infectious Diseases [USAMRIID]) was isolated by
cleavage with the restriction enzymes NdeI and NotI. The fragment was sub-
cloned into a pCR vector containing the 5 untranslated region (UTR) of the
psbA gene and then inserted (using NotI and EcoRV) into the universal chlo-
roplast vector pLD to create pLDS-F1V. The chloroplast expression vector
pLDS-F1V was bombarded into Petit Havana and LAMD (low-nicotine variety)
Nicotiana tabacum leaves as described elsewhere (48, 85, 86). Transgenic shoots
were first tested by PCR to confirm transgene integration. Plants that were
confirmed to contain the F1-V transgene were transferred to pots and were
grown with a photoperiod consisting of 16 of h light and 8 h of darkness in a
growth chamber at 26°C or in a greenhouse.
Southern blot analysis. Total plant DNA was extracted from tobacco plants
using a DNeasy plant mini kit (Qiagen, Valencia, CA). Total plant DNA was
digested with BamHI and hybridized with the flanking sequence probe, which
was obtained from the pUC-Ct vector by digesting it with BamHI and BglII,
which yielded a 0.81-kb fragment. The probe was prepared by random primed
32P labeling (Ready-To-Go DNA labeling beads; Amersham Biosciences, Pitts-
burgh, PA). The probe was hybridized to the membrane using the Quick-hyb
solution and protocol (Stratagene, La Jolla, CA). The radiolabeled blots were
exposed to X-ray film and then developed.
Immunoblot analysis. The immunoblot analysis protocol has been described
previously (48, 85, 86). Plant extraction buffer (PEB) (48, 85, 86) was made fresh
on the day of the analysis. Extraction was performed using a ratio of 100 mg of
leaf material to 200 l of PEB. Transgenic protein was detected using polyclonal
serum raised against F1 in rabbits (USAMRIID).
ELISA. Dilutions of plant crude extracts ranging from 1:5 to 1:5,000 were
made in coating buffer (48, 85, 86). Recombinant F1-V (standard) was also
diluted in coating buffer. An indirect ELISA was performed as described previ-
ously (48, 85, 86). The transgenic protein was detected using the anti-F1 poly-
clonal primary antibody.
Estimation of TSP. The total soluble protein (TSP) in plant crude extracts was
determined by the Bio-Rad protein assay as previously described (48, 85, 86).
Bovine serum albumin (Sigma Chemical, St. Louis, MO) was used as a standard
at concentrations ranging from 0.05 to 0.5 mg/ml.
Lyophilization and enrichment of transgenic crude extracts. To concentrate
the soluble protein in transgenic leaf material, 28.99 g of transgenic leaf material
was extracted in 75 ml of PEB. Aliquots (10 ml) were transferred to 50-ml conical
tubes and lyophilized to obtain a final volume of 1.5 ml. The concentrated
extracts were then pooled, loaded onto Centricon 50-kDa molecular weight
cutoff (MWCO) columns (Millipore, Billerica, MA), and centrifuged for 10 min
at 5,000  g. The flowthrough fraction was collected and run through the same
column a second time. The retentate fractions were collected, pooled, and
loaded onto 100-kDa MWCO columns, and the process was repeated. All
flowthrough and retentate fractions were analyzed for the presence of F1-V by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), immu-
noblot analysis, and ELISA.
Adsorption of enF1-V protein to adjuvant. F1-V enriched from transgenic
tobacco crude extract (enF1-V) was mixed with Alhydrogel (AlH) (Sigma Chem-
ical, St. Louis, MO) diluted 1:4 in phosphate-buffered saline (PBS) and incu-
bated at 4°C with gentle rocking overnight. The samples were then centrifuged at
2,000  g for 5 min at 4°C, and the protein-adsorbed pellet was resuspended in
PBS to a final concentration of 250 g/ml. The adsorption efficiency was calcu-
lated on the basis of the total amount of protein added to the adjuvant compared
with the protein remaining in the supernatant after adsorption.
Immunization. Female Hsd:ND4 Swiss Webster mice weighing 18 to 20 g each
were purchased from Harlan Sprague Dawley (Indianapolis, IN). Mice were
divided into the following five treatment groups: group 1, mice given s.c. enF1-V
prime and s.c. enF1-V boost doses (s.c. F1-V group) (10 animals); group 2, mice
given s.c. enF1-V prime and oral F1-V boost doses (oral F1-V group) (10
animals); group 3, mice given s.c. enF1-V prime and oral wild-type boost doses
(oral WT group) (10 animals); group 4, mice given s.c. AlH prime and s.c. AlH
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boost doses (s.c. AlH group) (5 animals); and group 5, untreated mice (5 ani-
mals).
s.c. injections were delivered as follows. Doses of chloroplast-derived enF1-V
adsorbed to AlH were diluted in 200 l of PBS and injected into the scruff of the
neck using a tuberculin syringe equipped with a 27-gauge needle. A single 25-g
dose of enF1-V was delivered on day 0 as the vaccine prime dose to animals in
groups 1 to 3; boosts of 10 g of enF1-V per dose were given to animals in group
1. Group 4 animals received equivalent amounts of AlH in the absence of F1-V.
Mice in groups 1 and 4 received four s.c. boosts, on days 14, 28, 126, and 164.
The doses used for oral delivery were prepared as follows. Leaf material from
transgenic or wild-type plants was ground in liquid nitrogen in cold, autoclaved
mortars and pestles. The pulverized leaf material was stored at 80°C until the
day of immunization. Oral doses (500 mg each) of either transgenic (group 2) or
nontransgenic (group 3) leaf material were resuspended in sterile PBS (250 l)
and homogenized for 5 min with an OMNI International GLH-2596 probe to
disperse the plant cells. The plant cell suspension (without clumps) was stored on
ice until oral gavage. The oral doses were delivered by using a tuberculin syringe
equipped with a 20-gauge bulb-tipped gastric gavage needle. Mice in groups 2
and 3 received eight oral boosts, on days 8, 15, 22, 29, 119, 126, 164, and 171.
Mice were shipped to USAMRIID on day 182.
Determination of antibody titers. Blood samples were obtained on day 7
before vaccination and days 21, 43, and 140 after vaccination. Blood was col-
lected from the retroorbital plexus of anesthetized mice (4% isoflurane) in
Microtainer serum separation tubes (Becton-Dickinson, Franklin Lakes, NJ).
The samples were allowed to clot for a minimum of 30 min at room temperature
and then centrifuged at 13,000  g for 2 min. The serum was transferred to fresh
tubes and either placed on ice or stored at 80°C.
Serum levels of F1-, V-, and F1-V-specific IgG1 and F1-V-specific IgG2a and
IgA were determined by ELISA. Purified recombinant F1, V, or F1-V (100 ng),
diluted in coating buffer, was incubated overnight at 4°C. Fivefold dilutions of
serum (beginning with 1:100 in PBS) were then aliquoted and incubated over-
night at 4°C. The secondary antibody was either anti-mouse IgG1 or IgG2a or
IgA. To compare the levels of antibodies of different isotypes, dilutions of
purified IgG1, IgG2a, and IgA were incubated overnight at 4°C, followed by
addition of secondary antibody (anti-IgG1, anti-IgG2a, and anti-IgA, respec-
tively).
Bacterial challenge. Y. pestis CO92 was prepared and used in accordance with
a previously reported procedure (2). Briefly, bacteria were harvested from tryp-
tose blood agar base (Difco Laboratories, Detroit, MI) slants and inoculated into
5 ml of heart infusion broth (HIB) (Difco), and the concentration was adjusted
to an optical density at 620 nm of 1.0 (approximately 109 CFU/ml). For aerosol
challenges, 2 ml of the HIB bacterial suspension was used to inoculate flasks
containing 100 ml HIB supplemented with 0.2% xylose. The broth cultures were
grown for 24 h in a 28°C shaker at 100 to 150 rpm. The concentration of pelleted
cells was adjusted to an optical density at 620 nm of 10.0 (approximately 1010
CFU/ml), and the preparations were diluted to produce the aerosolized doses
reported below. Antifoam agent A (Sigma) was added to a final concentration of
0.2% (vol/vol) to the bacterial suspension just before the aerosol challenges. The
aerosol challenges were conducted by whole-body exposure of mice to a small-
particle aerosol (median diameter, 1.2 m). Up to 40 unanesthetized mice were
challenged simultaneously inside a class III biological safety cabinet. Mice from
various groups were divided into different cages to minimize exposure differ-
ences. The inhaled doses for each exposure were estimated using Guyton’s
formula (33). Mice were observed twice daily for 21 days after exposure for signs
of morbidity or mortality. Any mouse found to be recumbent was humanely
euthanized.
Calculation of bacterial burden. Homogenates (10%) of whole spleen tissue
were plated in duplicate at the indicated dilutions on sheep blood agar plates.
The plates were incubated at 28°C for 48 h, and colonies were counted. The total
bacterial burden per gram of spleen was calculated by multiplying the plate count
by the appropriate dilution factor.
Statistical analysis. Pearson analysis was conducted to calculate correlation
coefficients comparing survival postchallenge and individual mouse day 140
postprime immunization F1-V-specific antibody titers. Fisher exact tests with
step-down Bonferroni adjustments were used to compute statistical differences
between observed survival rates. Survival curves were processed using Kaplan-
Meier survival analysis with log rank tests and step-down Bonferroni adjust-
ments. Statistical significance was considered a P value of 0.05, as indicated
below.
Care and treatment of animals. This research was conducted in compliance
with the Animal Welfare Act and other federal statutes and regulations relating
to animals and experiments involving animals and adhered to principles stated in
the Guide for the Care and Use of Laboratory Animals (National Research Coun-
cil, 1996). The animals received food and water ad libitum for the duration of the
study.
RESULTS
Assessment of transgenic plants. The F1-V fusion gene was
cloned into the universal chloroplast vector pLD-CtV to pro-
duce the final vector, pLDS-F1V (Fig. 1A), which was used for
particle bombardment. In this construct, the trnI and trnA
genes were used as flanking sequences for homologous recom-
bination with the native chloroplast genome. The aadA gene
conferring spectinomycin resistance was used for selection.
True chloroplast transformants were distinguished from nu-
clear transformants and mutants by PCR (data not shown).
PCR was also employed to ensure integration of the F1-V
fusion gene (data not shown). Confirmed Petit Havana and
LAMD (12) transgenic shoots were transferred to rooting me-
dium and then to either growth chambers or the greenhouse.
In order to evaluate homoplasmy, total DNA extracted from
untransformed and transgenic lines was probed with chloro-
plast flanking sequences (Fig. 1A). Homoplasmic lines of both
cultivars contained both 9.5- and 1.5-kb fragments without the
8-kb fragment observed in untransformed lines (Fig. 1B).
The light-regulated 5 UTR and promoter of the psbA gene
were used to enhance transcription and translation; the 3
UTR conferred transcript stability. The prokaryotic chloro-
plast favors AT-rich sequences, which reflects the tRNA abun-
dance. Therefore, the F1-V fusion gene, containing 65% AT,
was expected to be expressed well in chloroplasts. Mature
leaves always had the highest level of expression of F1-V, and
the highest content was on day 3 with continuous illumination
(an average of 14.8% of the TSP) (Fig. 2). The psbA 5 UTR
accounted for both the high expression of F1-V and the change
in expression during continuous illumination.
Enrichment of F1-V. Pooled chloroplast transgenic lines
containing a mixture of young, mature, and old leaves were
further analyzed for protein expression. Crude extracts of 223
mg of transgenic leaf material contained about 11 mg/ml of
TSP or 404 g/ml of F1-V, equivalent to 3.68% of the TSP or
1.01 mg F1-V per g of freeze-dried leaf material. The lyophi-
lization procedure did not degrade the F1-V protein; no
cleaved product was detected in lyophilized crude extracts by
immunoblot analysis (Fig. 3A). The lyophilized extract was
then enriched for F1-V using MWCO columns. Immunoblot
analysis of the various fractions indicated that F1-V was
present in the 100-kDa fraction but not in the 50- to 100-kDa
fraction (Fig. 3B). This may have been due to protein aggre-
gation, which is commonly observed in transgenic leaf extracts
due to high concentrations. Alternatively, it has been reported
that during purification F1-V antigens exist principally as
dimers and tetramers when they are expressed in E. coli (66).
Dilutions of enF1-V were analyzed by SDS-PAGE, and there
was a prominent band at 53 kDa (Fig. 3C), corresponding to
the size of the F1-V fusion protein. A comparison of the F1-V
content of leaf crude extracts with chloroplast-derived enF1-V
demonstrated that the enrichment procedure resulted in a
nearly 80% improvement in the concentration of transgenic
protein in the sample (3.68% versus 18.23% of the TSP).
Animal vaccinations. Mice were distributed across five treat-
ment groups, four of which received primary s.c. vaccinations.
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s.c. doses contained enF1-V adsorbed to AlH as an adjuvant,
which has been shown to increase the availability and stability
of an antigen(s) (32). Each of the treated animals received an
s.c. priming dose, which served to induce an initial immune
response in groups 1 to 3 to F1-V. Groups of mice received
either four s.c. boosts or eight oral boosts. Oral doses (oral
F1-V group) were delivered twice as frequently as s.c. doses
because of the reduced efficiency of antigen processing by the
gut mucosa (72). In addition, as s.c. boosts were delivered with
an adjuvant, doubling the number of oral doses was considered
adequate compensation for the absence of mucosal adjuvant.
We determined the serum titers of antigen-specific IgG1,
IgG2a, and IgA antibodies at various time points. Although
mice were immunized with the F1-V fusion protein, we as-
sessed the IgG1 levels based on specificity to three discrete
antigens, F1, V, and F1-V. No animal had detectable levels of
F1-, V-, or F1-V-specific IgG1 in its preimmune serum (Fig.
4A, 4B, and 4C, respectively), indicating that there was no
prior exposure to Y. pestis. There was no statistically significant
difference between the F1- and V-specific IgG1 titers at any of
the time points tested (P  0.05 in all cases).
Following the primary immunization mice received a series
of either four s.c. or eight oral boosts. Throughout the sched-
ule, there was an increase in the IgG titers in vaccinated mice,
which peaked at day 140 (Fig. 4). The only exception was
F1-specific IgG1, whose titers were similar at all time points
tested (Fig. 4A). An analysis of the binding affinities of the
secondary antibodies indicated that the anti-IgG1 antibody
bound purified IgG1 with approximately 40% greater affinity
than it bound the IgG2a antibody pair (data not shown). Serum
antibody titers were therefore adjusted to reflect the different
binding affinities.
Mice in the s.c. F1-V and oral F1-V groups had significantly
higher (2 logs) serum F1-V-specific IgG1 titers than IgG2a
titers (compare Fig. 4C and 4D). The development of high
titers of circulating IgG1 antibody was associated with protec-
tion (r 	 0.71), while the development of circulating IgG2a
antibody was not (r 	 0.15). Of the three mice in the s.c. F1-V
FIG. 1. Evaluation of transgene integration and homoplasmy in the T0 (first) generation of both cultivars. DNA extracted from transformed
and untransformed plants were probed with the flanking sequence probe (A). Southern blot analysis of transgenic lines in lanes 1 to 3 (Petit
Havana) and lanes 5 to 7 (LAMD) produced restriction fragments that were 9.5 and 1.5 kb long (B). Wild-type Petit Havana (lane 4) and LAMD
(lane 8) plants produced only the 8-kb fragment.
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group with the highest day 140 IgG1 titers, two survived (Fig.
4C and Table 1). Fecal IgA levels were also assessed and were
below the limit of detection for most animals (data not shown).
However, we did observe serum levels of F1-V-specific IgA
(Fig. 4E). The IgA titers did not vary significantly (P  0.05)
between groups and were weakly correlated with protection
(r 	 0.26).
Aerosol challenge. The 50% lethal dose (LD50) for a Swiss
Webster mouse for whole-body exposure to aerosolized Y.
pestis CO92 is 6.8  104 inhaled CFU. The calculated inhaled
dose for each mouse was 1.02  106 CFU or 15 LD50. Doses in
this range have been used previously for successful aerosol Y.
pestis challenge (3, 36, 75).
Mice were challenged on day 189. Following aerosol chal-
lenge, mice were observed twice daily for Y. pestis-dependent
morbidity and mortality. The challenge dose was sufficient to
induce death in untreated control animals, and the mean time
to death (MTD) was 3 days (Fig. 5), which is consistent with
our previous observations for untreated mice (35). Gross
pathological examination of mice that succumbed to the chal-
lenge revealed significant lung damage consistent with primary
plague pneumonia (data not shown). Lungs of mice that sur-
vived until the end of the observation period appeared to be
grossly normal (data not shown).
All control animals died as a result of pathogenic Y. pestis
challenge by day 8 postchallenge. At that time, three of nine
mice (33%) that received enF1-V delivered as s.c. boosts with
adjuvant survived (Fig. 5). The protection was statistically sig-
nificant compared to mice that received adjuvant only (P 	
0.0438) or untreated controls (P 	 0.0411). Seven of eight mice
(88%) in the oral F1-V group survived until the end of the
challenge experiment (day 22), even without adjuvant. The
single mouse that succumbed during the observation period
died on day 14 (while the MTD for control animals was 3 days),
and this animal had a bacterial count of 1.60  107 CFU/g,
which was several logs less than the count for control animals
(mean bacterial count, 2.17  1010 CFU/g). Both survival and
MTD were statistically significant when the mice were com-
pared to all three control groups (P  0.0001). There was also
a statistically significant difference between the oral F1-V and
s.c. F1-V groups in terms of survival rate and MTD (P 
0.0001). Mice that survived the observation period were found
to be free of infection by direct plating of spleen tissue (Table
1). The plant-derived vaccine appeared to reduce the bacterial
burden in vaccinates that did succumb to infection. A compar-
ison of the Y. pestis CFU counts for the spleens of control
animals and vaccinates showed that there was an approxi-
mately 2-log reduction in the mean bacterial burden of the
vaccinates (Table 1).
DISCUSSION
This study demonstrated that oral booster doses of Y. pestis-
derived antigens were at least as effective at eliciting protective
antigen-specific antibody responses as needle-based s.c. doses
of the same antigens. In addition, we found for the first time
that a plant-based vaccine against the etiologic agent of plague
successfully protected mice from lethal Y. pestis challenge. The
levels of F1-V in chloroplasts—up to 14.8% of the TSP—
enabled the delivery of sufficient amounts of vaccine antigens
in intact plant cells.
We observed that oral boosts of transgenic plant material
containing the plague fusion antigen F1-V without adjuvant
performed as well as s.c. boosts containing chloroplast-derived
enF1-V with adjuvant at eliciting a predominant IgG1 titer in
the serum of vaccinates. This type of response is indicative of
an ongoing TH2 response (78) and, in s.c. vaccinated animals,
is typical of AlH-adjuvanted vaccines (32, 53). The TH2 re-
FIG. 2. Quantitation of chloroplast-synthesized F1-V by ELISA. The quantity of F1-V is expressed as a percentage of the TSP. For continuous
illumination, leaf material was sampled on days 0, 1, 3, and 5 for young, mature, and old leaves.
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sponse, specifically mediated by serum levels of F1-V-specific
IgG1, has been shown to protect against both s.c. (95) and
aerosolized (3, 93) Y. pestis challenge. Our results corroborate
these findings. Orally boosted mice had similar or, in some
cases, higher levels of antigen-specific IgG1. Further, these
responses were consistent across the various antigens tested,
F1, V, and F1-V. The anti-F1 and anti-V IgG1 responses were
not significantly different from one another (P  0.05), indi-
cating that the individual components of the F1-V fusion pro-
tein had relatively equal immunogenicities.
The IgG1 levels were generally 2 to 3 logs higher than the
corresponding IgG2a levels. Not surprisingly, animals with the
highest IgG1 titers were more likely to survive challenge with
live Y. pestis (r 	 0.71) (Table 1). Overall, oral F1-V boosters
yielded somewhat higher IgG1 titers, more survivors, and a
longer MTD than s.c. F1-V boosters. Oral WT group control-
boosted mice had the lowest IgG1 titers of the three vaccinated
mice, the fewest survivors, and the shortest MTD. Collectively,
these results may suggest that the route of immunization or the
adjuvant plays a critical role in driving the formation of a
protective response in which both IgG1 and IgG2a are present.
It is important to note, however, that the oral boosts in our
study did not contain adjuvant, nor was the acidic pH of the gut
neutralized, which has been done in other oral vaccination
schemes (50, 96).
Because of the severe pathogenicity of Y. pestis, treatment of
plague is a high priority. The use of antimicrobial agents began
in 1938 (65) and has led to a dramatic drop in human mortality.
Today, the worldwide fatality rate attributable to plague has
fallen to less than 8% (26). Natural isolates of Y. pestis are
uniformly susceptible to all antimicrobial agents active against
gram-negative bacteria (8, 26). However, a “natural” strain
resistant to multiple antibiotics was isolated in 1995 in the
Ambalavao district of Madagascar (27). The possibility of the
occurrence of such multidrug-resistant strains in the natural
environment, the ease of generating such strains under labo-
ratory conditions (39, 41), and the potential use of such strains
for bioterrorist attack, together with the rapidity and high
lethality of the disease (for a review, see reference 5), indicate
that it is necessary to search for alternatives to antibiotics.
Immunization is now one of the major approaches being
pursued to deal with potential Y. pestis infection. Use of the
serum of vaccinated rabbits to cure animals infected with Y.
pestis was first attempted more than 100 years ago (97). Since
then, several antigens have been shown to be able to produce
protective immunity. Among these antigens are the F1 capsu-
lar (58, 76) and LcrV (or V) antigens (51, 61, 84), both of which
also contain immunodominant epitopes (38, 73, 74, 98). Pas-
sive administration of antibodies against target antigens pro-
tects macrophages from Y. pestis-induced cell death, promotes
phagocytosis (13, 64, 88), and protects animals against both
bubonic plague and pneumonic plague (4, 25, 37, 61, 69, 84,
91). However, therapy based on a single antibody against a
single antigen or epitope will be ineffective in the case of
infection with a virulent strain lacking the antigen or express-
ing a different serological variant of the antigen (6, 25, 69).
Human plague vaccines based on either a live, attenuated
strain or a killed, whole-cell preparation (for a review, see
reference 5) are no longer commercially available. Given the
severity of the infection and the potential of the organism as a
bioterrorist agent, we describe a subunit vaccine produced in
transgenic tobacco chloroplasts. This vaccine offers the advan-
tage of employing two defined antigens, F1 and V, that are able
to elicit high-level protection. Subunit vaccines have been
shown to be less reactogenic than the former whole-cell vac-
cines (6, 90, 91).
There have been several reports of s.c., intranasal, and oral
vaccination strategies protecting animals from Y. pestis chal-
lenge (for a review, see reference 82). Oral plague immuniza-
tion studies of attenuated Salmonella vaccines have shown that
these vaccines are effective (28, 60, 81). But there are clinical
concerns for vaccination of special-needs populations, such as
the young, the old, pregnant women, and immunocompro-
mised individuals. Another practical concern is plasmid main-
tenance and stability. We believe that the use of orally deliv-
ered plant-based vaccines may obviate these concerns and that
such vaccines may be less reactogenic in the general popula-
tion.
FIG. 3. Enrichment of the chloroplast-derived F1-V antigen.
Transgenic plant crude extracts were lyophilized and then sequentially
centrifuged through 50- and 100-kDa MWCO columns. (A) Immuno-
blot analysis of lyophilized crude extracts. Lanes 1 to 5, dilutions of
lyophilized crude extract (1:1, 1:10, 1:100, 1:1,000, and 1:5,000); lanes
6 and 7, 750 and 250 ng, respectively, of recombinant F1-V purified
from E. coli. (B) Immunoblot analysis of enriched plant extracts ana-
lyzed by SDS-PAGE, followed by immunoblotting. Lanes 1 to 3, dilu-
tions of 100-kDa column retentate (1:5, 1:10, and 1:50); lanes 4 to 6,
dilutions of 100-kDa column wash (1:5, 1:10, and 1:50); lane 7, 750
ng of recombinant F1-V purified from E. coli. (C) Chloroplast-derived
enF1-V samples were analyzed by SDS-PAGE, followed by staining
with Coomassie blue. Lanes 1 to 5, dilutions of lyophilized crude
extract (1:5, 1:10, 1:100, 1:500, and 1:50,000); lanes 6 and 7, 750 and
250 ng, respectively, of recombinant F1-V purified from E. coli; lanes
M, molecular weight markers.
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FIG. 4. Quantitation of serum antibody titers after immunization. Mice were immunized as described in the text. On days 21, 43, and 140, blood
was collected and the serum was analyzed for the presence of (A) F1-specific IgG1, (B) V-specific IgG1, (C) F1-V-specific IgG1, (D) F1-V-specific
IgG2a, and (E) F1-V-specific IgA antibodies. IgG titers were calculated by determining the reciprocal of the highest dilution that resulted in a
difference between each treatment group and untreated group of 0.25 optical density unit; IgA titers were calculated based on a difference between
each treatment group and untreated group of 0.1 optical density unit. SC F1-V, s.c. enF1-V prime dose and s.c. enF1-V boosts; Oral F1-V, s.c.
enF1-V prime dose and oral F1-V boosts; Oral WT, s.c. enF1-V prime dose and oral wild-type boosts; SC AlH, s.c. AlH prime dose and s.c. AlH
boosts. Ab, antibody.
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One might expect that protection of the mucosal surface
would be critical against aerosolized Y. pestis. Mucosal protec-
tion is normally mediated by local production of secretory IgA
(56). Although IgA is the predominant humoral defense mech-
anism at mucosal surfaces, local IgM and IgG and, in the lower
respiratory tract, serum IgG can also contribute significantly to
immune defense (40). Indeed, serum IgG1 has been shown to
be the predominant isotype produced in response to recombi-
nant plague vaccines and to be associated with protection
against aerosolized Y. pestis (3, 91, 92). The high IgG1 titers
elicited in this study confirmed these findings and indicate that
there was appropriate immune modulation by our plant-based
vaccine.
The contribution of IgA to the protective response to plague
is less clear. Previous oral plague vaccine strategies have been
shown to induce low levels of serum IgA, although the expres-
sion was not examined for an association with parenteral pro-
tection (60). In our study, we observed low but measurable
levels of F1-V-specific IgA in the serum; however, this re-
sponse correlated weakly with protection (r 	 0.26). More
recently, an attenuated Salmonella oral vaccine expressing
both F1 and V antigens was shown to induce fecal IgA and
serum IgG1/IgG2/IgG3 responses, as well as protection against
both bubonic plague and pneumonic plague (96). Again, no
direct comparison of IgA with survival was made. Another
recent study in which F1-V was mixed with the mucosal adju-
vant Protollin and administered intranasally did show that
there was a statistical association between lung IgA levels and
protection (43). This finding is complicated by the fact that
there were also statistical associations between lung and serum
IgG levels and protection. Collectively, these data suggest that
an appropriate mucosal adjuvant may be required to induce
secretory IgA. The ability to passively protect mice with IgA
alone may need to be shown to firmly establish the contribu-
tion of IgA to overall protection from plague.
Other studies have suggested the importance of the route of
immunization to the overall levels and types of antibody to F1
and V, as well as protection against subsequent Y. pestis chal-
lenge (23, 24). It is becoming increasingly clear that mixing of
vaccine routes can have a positive effect on both antibody
production and protection. It has been previously reported
that in F1-V vaccinations, heterologous prime-boost regimens
are at least as effective as homologous boost regimens for
inducing serum anti-F1-V IgG1 responses (29, 30). In this
study, all vaccinated mice received an initial s.c. injection,
which effectively induced a potent systemic humoral response
(Fig. 4). Oral delivery resulted in the highest levels of serum
IgG1 and IgG2a of all groups but negligible titers of F1-V-
specific IgA in the feces of animals. At first, this finding ap-
pears to be paradoxical. However, the route chosen for induc-
tion of peripheral immunity may delay or prevent the induction
of mucosal immunity (10, 54, 55). Indeed, s.c. immunizations
followed by oral boosts have been shown to suppress local
intestinal antigen-specific IgA responses (34, 46). The latter
TABLE 1. Antibody titers and bacterial (Y. pestis) counts for immunized mice
Group Mouse Day of deathafter challenge
Antibody titera Y. pestis concn (CFU/g)b
IgG1 IgG2a IgA Spleen Group mean
1 (s.c. F1-V) 1.1 —c 100,000 1,000 100 0 0
3.1 — 50,000 500 0 0
7.1 — 250,000 500 0 0
2 (oral F1-V) 1.2 — 50,000 500 100 0 0
2.2 — 250,000 5,000 1,000 0
2.4 — 250,000 2,500 0 0
3.2 — 250,000 500 100 0
5.2 — 250,000 1,000 0 0
6.2 — 250,000 1,000 0 0
7.2 — 250,000 1,000 1,000 0
4 (s.c. AlH) 1.5 3 0 0 0 6.02  1010 2.17  1010
2.5 3 0 0 0 1.27  1010
3.5 3 0 0 0 1.30  1010
7.4 5 0 0 0 9.00  108
5 (untreated) 5.5 3 0 0 0 1.94  1010 1.39  1010
6.5 3 0 0 0 1.05  1010
7.5 3 0 0 0 6.30  109
8.5 3 0 0 0 1.94  1010
1 (s.c. F1-V) 1.4 6 50,000 0 100 1.60  109 8.00  108
8.1 6 50,000 500 0 5.60  105
2 (oral F1-V) 4.2 13 50,000 500 0 1.60  107 1.60  107
3 (oral WT) 3.3 3 10,000 1,000 0 3.70  1010 1.85  1010
4.4 8 50,000 250 0 5.90  105
a The antibody titer was assessed on day 140 after prime immunization.
b At the time of death, spleens were excised from representative animals of each group to determine the bacterial burden.
c —, animals euthanized on day 22 postchallenge had no symptoms of infection.
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observation appears to support our finding that there was a
limited IgA response following oral boosts of F1-V.
This report of a plant-based plague vaccine demonstrates for
the first time that high-level protection of mice from the lethal
pathogenic effects of aerosol challenge can be elicited by oral
delivery. Virus-based plant expression systems have been used
successfully to confer protection against Y. pestis challenge in
guinea pigs and macaques upon s.c. immunization with puri-
fied F1-V antigens (57, 75). There is one previous report of an
s.c. prime-oral boost strategy, involving Agrobacterium-trans-
formed tomato nuclei, but no pathogen challenge was per-
formed (1). The prime-boost strategy that we employed was
designed to maximize antigen delivery to the immune system
while minimizing processing time and costs. The efficacy of this
strategy also indicates that oral immunization boosts are at
least as effective as s.c. boosts for eliciting systemic humoral
responses. In addition, if oral boosts are found to consistently
perform at least as well as s.c. boosts, then the use of needle-
based vaccines and the substantial costs associated with their
use may need to be reexamined. Chloroplast technology is
therefore an ideal system for oral delivery of vaccines.
ACKNOWLEDGMENTS
This investigation was supported in part by USDA grant 3611-
21000-017-00D and NIH grant 5R01 GM 63879-06 to Henry Daniell
and by DTRA research plan A2-X002-04-RD-B to Jeffrey Adamovicz.
We are grateful to Bob Banks of the UCF Wild Animal Facility for
help with the handling of animals.
REFERENCES
1. Alvarez, M. L., H. L. Pinyerd, J. D. Crisantes, M. M. Rigano, J. Pinkhasov,
A. M. Walmsley, H. S. Mason, and G. A. Cardineau. 2006. Plant-made
subunit vaccine against pneumonic and bubonic plague is orally immuno-
genic in mice. Vaccine 24:2477–2490.
2. Anderson, G. W., Jr., D. G. Heath, C. R. Bolt, S. L. Welkos, and A. M.
Friedlander. 1998. Short- and long-term efficacy of single-dose subunit vac-
cines against Yersinia pestis in mice. Am. J. Trop. Med. Hyg. 58:793–799.
3. Anderson, G. W., Jr., S. E. Leary, E. D. Williamson, R. W. Titball, S. L.
Welkos, P. L. Worsham, and A. M. Friedlander. 1996. Recombinant V
antigen protects mice against pneumonic and bubonic plague caused by
F1-capsule-positive and -negative strains of Yersinia pestis. Infect. Immun.
64:4580–4585.
4. Anderson, G. W., Jr., P. L. Worsham, C. R. Bolt, G. P. Andrews, S. L.
Welkos, A. M. Friedlander, and J. P. Burans. 1997. Protection of mice from
fatal bubonic and pneumonic plague by passive immunization with mono-
clonal antibodies against the F1 protein of Yersinia pestis. Am. J. Trop. Med.
Hyg. 56:471–473.
5. Anisimov, A. P., and K. K. Amoako. 2006. Treatment of plague: promising
alternatives to antibiotics. J. Med. Microbiol. 55:1461–1475.
6. Anisimov, A. P., L. E. Lindler, and G. B. Pier. 2004. Intraspecific diversity of
Yersinia pestis. Clin. Microbiol. Rev. 17:434–464.
7. Arntzen, C., S. Plotkin, and B. Dodet. 2005. Plant-derived vaccines and
antibodies: potential and limitations. Vaccine 23:1753–1756.
8. Bames, A. M., and T. J. Quan. 1992. Plague, p. 1285–1291. In S. Gorbach, J.
Bartlett, and N. Blacklow (ed.), Infectious diseases. W. B. Saunders Com-
pany, Philadelphia, PA.
9. Benner, G. E., G. P. Andrews, W. R. Byrne, S. D. Strachan, A. K. Sample,
D. G. Heath, and A. M. Friedlander. 1999. Immune response to Yersinia
outer proteins and other Yersinia pestis antigens after experimental plague
infection in mice. Infect. Immun. 67:1922–1928.
10. Chase, M. W. 1946. Inhibition of experimental drug allergy by prior feeding
of the sensitizing agent. Proc. Exp. Biol. Med. 61:257–259.
11. Chebolu, S., and H. Daniell. 2007. Stable expression of Gal/GalNAc lectin of
Entamoeba histolytica in transgenic chloroplasts and immunogenicity in
mice towards vaccine development for amoebiasis. Plant Biotechnol. J.
5:230–239.
12. Collins, G. B., P. D. Legg, and M. C. Kasperbauer. 1974. Tobacco hybrid
LAMD-609. Crop Sci. 14:72–80.
13. Cowan, C., A. V. Philipovskiy, C. R. Wulff-Strobel, Z. Ye, and S. C. Straley.
2005. Anti-LcrV antibody inhibits delivery of Yops by Yersinia pestis KIM5 by
directly promoting phagocytosis. Infect. Immun. 73:6127–6137.
14. Daniell, H. 2002. Molecular strategies for gene containment in transgenic
crops. Nat. Biotechnol. 20:581–586.
15. Daniell, H. 2006. Production of biopharmaceuticals and vaccines in plants via
the chloroplast genome. Biotechnol. J. 1:1071–1079.
16. Daniell, H. 2007. Transgene containment by maternal inheritance: effective
or elusive? Proc. Natl. Acad. Sci. USA 104:6879–6880.
FIG. 5. Mice receiving oral boosts of chloroplast-derived F1-V survived longer than mice receiving s.c. boosts. Animals were challenged with
15 LD50 of Y. pestis CO92 (whole-body LD50, 6.8  10
4 CFU), and their survival was monitored. Differences in survival between untreated animals
and immunized animals were statistically significant (P  0.05, as determined by the log rank test). Differences between animals boosted s.c. and
animals boosted orally were also significant (P  0.05). SC F1-V, s.c. enF1-V prime dose and s.c. enF1-V boosts; Oral F1-V, s.c. enF1-V prime
dose and oral F1-V boosts; Oral WT, s.c. enF1-V prime dose and oral wild-type boosts; SC AlH, s.c. AlH prime dose and s.c. AlH boosts.
3648 ARLEN ET AL. INFECT. IMMUN.
 on S
eptem






















17. Daniell, H., S. Chebolu, S. Kumar, M. Singleton, and R. Falconer. 2005.
Chloroplast-derived vaccine antigens and other therapeutic proteins. Vac-
cine 23:1779–1783.
18. Daniell, H., S.-B. Lee, T. Panchal, and P. O. Wiebe. 2001. Expression of the
native cholera toxin B subunit gene and assembly as functional oligomers in
transgenic tobacco chloroplasts. J. Mol. Biol. 311:1001.
19. De Cosa, B., W. Moar, S. B. Lee, M. Miller, and H. Daniell. 2001. Overex-
pression of the Bt cry2Aa2 operon in chloroplasts leads to formation of
insecticidal crystals. Nat. Biotechnol. 19:71–74.
20. Dhingra, A., A. R. Portis, Jr., and H. Daniell. 2004. Enhanced translation of
a chloroplast-expressed RbcS gene restores small subunit levels and photo-
synthesis in nuclear RbcS antisense plants. Proc. Natl. Acad. Sci. USA
101:6315–6320.
21. Du, Y., R. Rosqvist, and A. Forsberg. 2002. Role of fraction 1 antigen of
Yersinia pestis in inhibition of phagocytosis. Infect. Immun. 70:1453–1460.
22. Dufourmantel, N., B. Pelissier, F. Garcon, G. Peltier, J. M. Ferullo, and G.
Tissot. 2004. Generation of fertile transplastomic soybean. Plant Mol. Biol
55:479–489.
23. Eyles, J. E., G. J. E. Sharp, E. D. Williamson, I. D. Spiers, and H. Oya Alpar.
1998. Intranasal administration of poly-lactic acid microsphere co-encapsu-
lated Yersinia pestis subunits confers protection from pneumonic plague in
the mouse. Vaccine 16:698–707.
24. Eyles, J. E., I. D. Spiers, E. D. Williamson, and H. Oya Alpar. 1998. Analysis
of local and systemic immunological responses after intra-tracheal, intra-
nasal and intra-muscular administration of microsphere co-encapsulated
Yersinia pestis sub-unit vaccines. Vaccine 16:2000–2009.
25. Friedlander, A. M., S. L. Welkos, P. L. Worsham, G. P. Andrews, D. G.
Heath, G. W. Anderson, Jr., M. L. Pitt, J. Estep, and K. Davis. 1995.
Relationship between virulence and immunity as revealed in recent studies
of the F1 capsule of Yersinia pestis. Clin. Infect. Dis. 21(Suppl. 2):S178–
S181.
26. Galimand, M., E. Carniel, and P. Courvalin. 2006. Resistance of Yersinia
pestis to antimicrobial agents. Antimicrob. Agents Chemother. 50:3233–3236.
27. Galimand, M., A. Guiyoule, G. Gerbaud, B. Rasoamanana, S. Chanteau, E.
Carniel, and P. Courvalin. 1997. Multidrug resistance in Yersinia pestis
mediated by a transferable plasmid. N. Engl. J. Med. 337:677–681.
28. Garmory, H. S., K. F. Griffin, K. A. Brown, and R. W. Titball. 2003. Oral
immunisation with live aroA attenuated Salmonella enterica serovar Typhi-
murium expressing the Yersinia pestis V antigen protects mice against
plague. Vaccine 21:3051–3057.
29. Glynn, A., L. C. Freytag, and J. D. Clements. 2005. Effect of homologous and
heterologous prime-boost on the immune response to recombinant plague
antigens. Vaccine 23:1957–1965.
30. Glynn, A., C. J. Roy, B. S. Powell, J. J. Adamovicz, L. C. Freytag, and J. D.
Clements. 2005. Protection against aerosolized Yersinia pestis challenge fol-
lowing homologous and heterologous prime-boost with recombinant plague
antigens. Infect. Immun. 73:5256–5261.
31. Greenfield, R. A., and M. S. Bronze. 2003. Prevention and treatment of
bacterial diseases caused by bacterial bioterrorism threat agents. Drug Dis-
cov. Today 8:881–888.
32. Gupta, R. K., B. E. Rost, E. Relyveld, and G. R. Siber. 1995. Adjuvant
properties of aluminum and calcium compounds. Pharm. Biotechnol. 6:229–
248.
33. Guyton, A. C. 1947. Measurement of the respiratory volumes of laboratory
animals. Am. J. Physiol. 150:70–77.
34. Hamilton, S. R., J. H. Yardley, and G. D. Brown. 1979. Suppression of local
intestinal immunoglobulin A immune response to cholera toxin by subcuta-
neous administration of cholera toxoids. Infect. Immun. 24:422–426.
35. Heath, D. G., G. W. Anderson, J. M. Mauro, S. L. Welkos, G. P. Andrews, J.
Adamovicz, and A. M. Friedlander. 1998. Protection against experimental
bubonic and pneumonic plague by a recombinant capsular F1-V antigen
fusion protein vaccine. Vaccine 16:1131–1137.
36. Heine, H. S., A. Louie, F. Sorgel, J. Bassett, L. Miller, L. J. Sullivan, M.
Kinzig-Schippers, and G. L. Drusano. 2007. Comparison of 2 antibiotics that
inhibit protein synthesis for the treatment of infection with Yersinia pestis
delivered by aerosol in a mouse model of pneumonic plague. J. Infect. Dis.
196:782–787.
37. Hill, J., J. E. Eyles, S. J. Elvin, G. D. Healey, R. A. Lukaszewski, and R. W.
Titball. 2006. Administration of antibody to the lung protects mice against
pneumonic plague. Infect. Immun. 74:3068–3070.
38. Hill, J., S. E. Leary, K. F. Griffin, E. D. Williamson, and R. W. Titball. 1997.
Regions of Yersinia pestis V antigen that contribute to protection against
plague identified by passive and active immunization. Infect. Immun. 65:
4476–4482.
39. Hinnebusch, B. J., M.-L. Rosso, T. G. Schwan, and E. Carniel. 2002. High-
frequency conjugative transfer of antibiotic resistance genes to Yersinia
pestis in the flea midgut. Mol. Microbiol. 46:349–354.
40. Holmgren, J., and C. Czerkinsky. 2005. Mucosal immunity and vaccines. Nat.
Med. 11(4 Suppl.):S45–S53.
41. Hurtle, W., L. Lindler, W. Fan, D. Shoemaker, E. Henchal, and D. Norwood.
2003. Detection and identification of ciprofloxacin-resistant Yersinia pestis by
denaturing high-performance liquid chromatography. J. Clin. Microbiol. 41:
3273–3283.
42. Inglesby, T. V., D. T. Dennis, D. A. Henderson, J. G. Bartlett, M. S. Ascher,
E. Eitzen, A. D. Fine, A. M. Friedlander, J. Hauer, J. F. Koerner, M. Layton,
J. McDade, M. T. Osterholm, T. O’Toole, G. Parker, T. M. Perl, P. K.
Russell, M. Schoch-Spana, and K. Tonat. 2000. Plague as a biological weap-
on: medical and public health management. Working Group on Civilian
Biodefense. JAMA 283:2281–2290.
43. Jones, T., J. J. Adamovicz, S. L. Cyr, C. R. Bolt, N. Bellerose, L. M. Pitt,
G. H. Lowell, and D. S. Burt. 2006. Intranasal Protollin/F1-V vaccine elicits
respiratory and serum antibody responses and protects mice against lethal
aerosolized plague infection. Vaccine 24:1625–1632.
44. Kamarajugadda, S., and H. Daniell. 2006. Chloroplast-derived anthrax and
other vaccine antigens: their immunogenic and immunoprotective proper-
ties. Expert Rev. Vaccines 5:839–849.
45. Kanamoto, H., A. Yamashita, H. Asao, S. Okumura, H. Takase, M. Hattori,
A. Yokota, and K. Tomizawa. 2006. Efficient and stable transformation of
Lactuca sativa L. cv. Cisco (lettuce) plastids. Transgenic Res. 15:205–217.
46. Koster, F. T., and N. F. Pierce. 1983. Parenteral immunization causes anti-
gen-specific cell-mediated suppression of an intestinal IgA response. J. Im-
munol. 131:115–119.
47. Koya, V., M. Moayeri, S. H. Leppla, and H. Daniell. 2005. Plant-based
vaccine: mice immunized with chloroplast-derived anthrax protective antigen
survive anthrax lethal toxin challenge. Infect. Immun. 73:8266–8274.
48. Kumar, S., and H. Daniell. 2004. Engineering the chloroplast genome for
hyperexpression of human therapeutic proteins and vaccine antigens. Meth-
ods Mol. Biol. 267:365–383.
49. Kumar, S., A. Dhingra, and H. Daniell. 2004. Plastid-expressed betaine
aldehyde dehydrogenase gene in carrot cultured cells, roots, and leaves
confers enhanced salt tolerance. Plant Physiol. 136:2843–2854.
50. Lavelle, E. C., and D. T. O’Hagan. 2006. Delivery systems and adjuvants for
oral vaccines. Expert Opin. Drug Deliv. 3:747–762.
51. Leary, S. E., E. D. Williamson, K. F. Griffin, P. Russell, S. M. Eley, and R. W.
Titball. 1995. Active immunization with recombinant V antigen from
Yersinia pestis protects mice against plague. Infect. Immun. 63:2854–2858.
52. Limaye, A., V. Koya, M. Samsam, and H. Daniell. 2006. Receptor-mediated
oral delivery of a bioencapsulated green fluorescent protein expressed in
transgenic chloroplasts into the mouse circulatory system. FASEB J. 20:959–
961.
53. Lindblad, E. B. 2004. Aluminium adjuvants—in retrospect and prospect.
Vaccine 22:3658–3668.
54. MacDonald, T. T. 1982. Enhancement and suppression of the Peyer’s patch
immune response by systemic priming. Clin. Exp. Immunol. 49:441–448.
55. Mattingly, J. A., and B. H. Waksman. 1978. Immunologic suppression after
oral administration of antigen. I. Specific suppressor cells formed in rat
Peyer’s patches after oral administration of sheep erythrocytes and their
systemic migration. J. Immunol. 121:1878–1883.
56. Mestecky, J., and J. R. McGhee. 1987. Immunoglobulin A (IgA): molecular
and cellular interactions involved in IgA biosynthesis and immune response.
Adv. Immunol. 40:153–245.
57. Mett, V., J. Lyons, K. Musiychuk, J. A. Chichester, T. Brasil, R. Couch, R.
Sherwood, G. A. Palmer, S. J. Streatfield, and V. Yusibov. 2007. A plant-
produced plague vaccine candidate confers protection to monkeys. Vaccine
25:3014–3017.
58. Meyer, K. F., J. A. Hightower, and F. R. McCrumb. 1974. Plague immuni-
zation. VI. Vaccination with the fraction I antigen of Yersinia pestis. J. In-
fect. Dis. 129(Suppl.):S41–S45.
59. Molina, A., S. Hervas-Stubbs, H. Daniell, A. M. Mingo-Castel, and J. Vera-
mendi. 2004. High-yield expression of a viral peptide animal vaccine in
transgenic tobacco chloroplasts. Plant Biotechnol. J. 2:141–153.
60. Morton, M., H. S. Garmory, S. D. Perkins, A. M. O’Dowd, K. F. Griffin, A. K.
Turner, A. M. Bennett, and R. W. Titball. 2004. A Salmonella enterica
serovar Typhi vaccine expressing Yersinia pestis F1 antigen on its surface
provides protection against plague in mice. Vaccine 22:2524–2532.
61. Motin, V. L., R. Nakajima, G. B. Smirnov, and R. R. Brubaker. 1994. Passive
immunity to yersiniae mediated by anti-recombinant V antigen and protein
A-V antigen fusion peptide. Infect. Immun. 62:4192–4201.
62. Perry, R. D., and J. D. Fetherston. 1997. Yersinia pestis—etiologic agent of
plague. Clin. Microbiol. Rev. 10:35–66.
63. Pettersson, J., A. Holmstrom, J. Hill, S. Leary, E. Frithz-Lindsten, A. von
Euler-Matell, E. Carlsson, R. Titball, A. Forsberg, and H. Wolf-Watz. 1999.
The V-antigen of Yersinia is surface exposed before target cell contact and
involved in virulence protein translocation. Mol. Microbiol. 32:961–976.
64. Philipovskiy, A. V., C. Cowan, C. R. Wulff-Strobel, S. H. Burnett, E. J.
Kerschen, D. A. Cohen, A. M. Kaplan, and S. C. Straley. 2005. Antibody
against V antigen prevents Yop-dependent growth of Yersinia pestis. Infect.
Immun. 73:1532–1542.
65. Pollitzer, R. 1954. Plague. WHO Monogr. Ser. 22:1–698.
66. Powell, B. S., G. P. Andrews, J. T. Enama, S. Jendrek, C. Bolt, P. Worsham,
J. K. Pullen, W. Ribot, H. Hines, L. Smith, D. G. Heath, and J. J. Adamovicz.
2005. Design and testing for a nontagged F1-V fusion protein as vaccine
VOL. 76, 2008 EFFECTIVE PLAGUE VACCINATION 3649
 on S
eptem






















antigen against bubonic and pneumonic plague. Biotechnol. Prog. 21:1490–
1510.
67. Quesada-Vargas, T., O. N. Ruiz, and H. Daniell. 2005. Characterization of
heterologous multigene operons in transgenic chloroplasts: transcription,
processing, and translation. Plant Physiol. 138:1746–1762.
68. Rodrigues, C. G., C. M. Carneiro, C. T. Barbosa, and R. A. Nogueira. 1992.
Antigen F1 from Yersinia pestis forms aqueous channels in lipid bilayer
membranes. Braz. J. Med. Biol. Res. 25:75–79.
69. Roggenkamp, A., A. M. Geiger, L. Leitritz, A. Kessler, and J. Heesemann.
1997. Passive immunity to infection with Yersinia spp. mediated by anti-
recombinant V antigen is dependent on polymorphism of V antigen. Infect.
Immun. 65:446–451.
70. Ruhlman, T., R. Ahangari, A. Devine, M. Samsam, and H. Daniell. 2007.
Expression of cholera toxin B-proinsulin fusion protein in lettuce and to-
bacco chloroplasts—oral administration protects against development of
insulitis in non-obese diabetic mice. Plant Biotechnol. J. 5:495–510.
71. Ruiz, O. N., and H. Daniell. 2005. Engineering cytoplasmic male sterility via
the chloroplast genome by expression of 
-ketothiolase. Plant Physiol. 138:
1232–1246.
72. Rydell, N., and I. Sjoholm. 2004. Oral vaccination against diphtheria using
polyacryl starch microparticles as adjuvant. Vaccine 22:1265–1274.
73. Sabhnani, L., M. Manocha, K. Sridevi, D. Shashikiran, R. Rayanade, and
D. N. Rao. 2003. Developing subunit immunogens using B and T cell
epitopes and their constructs derived from the F1 antigen of Yersinia pestis
using novel delivery vehicles. FEMS Immunol. Med. Microbiol. 38:215–229.
74. Sabhnani, L., and D. N. Rao. 2000. Identification of immunodominant
epitope of F1 antigen of Yersinia pestis. FEMS Immunol. Med. Microbiol.
27:155–162.
75. Santi, L., A. Giritch, C. J. Roy, S. Marillonnet, V. Klimyuk, Y. Gleba, R.
Webb, C. J. Arntzen, and H. S. Mason. 2006. Protection conferred by re-
combinant Yersinia pestis antigens produced by a rapid and highly scalable
plant expression system. Proc. Natl. Acad. Sci. USA 103:861–866.
76. Simpson, W. J., R. E. Thomas, and T. G. Schwan. 1990. Recombinant
capsular antigen (fraction 1) from Yersinia pestis induces a protective anti-
body response in BALB/c mice. Am. J. Trop. Med. Hyg. 43:389–396.
77. Sing, A., D. Rost, N. Tvardovskaia, A. Roggenkamp, A. Wiedemann, C. J.
Kirschning, M. Aepfelbacher, and J. Heesemann. 2002. Yersinia V-antigen
exploits Toll-like receptor 2 and CD14 for interleukin 10-mediated immu-
nosuppression. J. Exp. Med. 196:1017–1024.
78. Snapper, C. M., F. D. Finkelman, and W. E. Paul. 1988. Differential regu-
lation of IgG1 and IgE synthesis by interleukin 4. J. Exp. Med. 167:183–196.
79. Straley, S. C., and W. S. Bowmer. 1986. Virulence genes regulated at the
transcriptional level by Ca2 in Yersinia pestis include structural genes for
outer membrane proteins. Infect. Immun. 51:445–454.
80. Streatfield, S. J. 2007. Approaches to achieve high-level heterologous pro-
tein production in plants. Plant Biotechnol. J. 5:2–15.
81. Taylor, V. L., R. W. Titball, and P. C. F. Oyston. 2005. Oral immunization
with a dam mutant of Yersinia pseudotuberculosis protects against plague.
Microbiology 151:1919–1926.
82. Titball, R. W., and E. D. Williamson. 2001. Vaccination against bubonic and
pneumonic plague. Vaccine 19:4175–4184.
83. Tregoning, J. S., P. Nixon, H. Kuroda, Z. Svab, S. Clare, F. Bowe, N.
Fairweather, J. Ytterberg, K. J. van Wijk, G. Dougan, and P. Maliga. 2003.
Expression of tetanus toxin fragment C in tobacco chloroplasts. Nucleic
Acids Res. 31:1174–1179.
84. Une, T., and R. R. Brubaker. 1984. Roles of V antigen in promoting viru-
lence and immunity in yersiniae. J. Immunol. 133:2226–2230.
85. Verma, D., and H. Daniell. 2007. Chloroplast vector systems for biotechnol-
ogy applications. Plant Physiol. 145:1129–1143.
86. Verma, D., N. P. Samson, V. Koya, and H. Daniell. 2008. A protocol for
expression of foreign genes in chloroplasts. Nat. Protoc. 3:739–758.
87. Watson, J., V. Koya, S. H. Leppla, and H. Daniell. 2004. Expression of
Bacillus anthracis protective antigen in transgenic chloroplasts of tobacco, a
non-food/feed crop. Vaccine 22:4374–4384.
88. Weeks, S., J. Hill, A. Friedlander, and S. Welkos. 2002. Anti-V antigen
antibody protects macrophages from Yersinia pestis-induced cell death and
promotes phagocytosis. Microb. Pathog. 32:227–237.
89. Williams, R. C., Jr., H. Gewurz, and P. G. Quie. 1972. Effects of fraction I
from Yersinia pestis on phagocytosis in vitro. J. Infect. Dis. 126:235–241.
90. Williamson, E. D. 2001. Plague vaccine research and development. J. Appl.
Microbiol. 91:606–608.
91. Williamson, E. D., H. C. Flick-Smith, C. LeButt, C. A. Rowland, S. M. Jones,
E. L. Waters, R. J. Gwyther, J. Miller, P. J. Packer, and M. Irving. 2005.
Human immune response to a plague vaccine comprising recombinant F1
and V antigens. Infect. Immun. 73:3598–3608.
92. Williamson, E. D., H. C. Flick-Smith, E. Waters, J. Miller, I. Hodgson, C. S.
Le Butt, and J. Hill. 2007. Immunogenicity of the rF1rV vaccine for plague
with identification of potential immune correlates. Microb. Pathog. 42:11–21.
93. Williamson, E. D., G. J. E. Sharp, S. M. Eley, P. M. Vesey, T. C. Pepper,
R. W. Titball, and H. O. Alpar. 1996. Local and systemic immune response
to a microencapsulated sub-unit vaccine for plague. Vaccine 14:1613–1619.
94. Williamson, E. D., and R. W. Titball. 2002. Vaccines against dangerous
pathogens. Br. Med. Bull 62:163–173.
95. Williamson, E. D., P. M. Vesey, K. J. Gillhespy, S. M. Eley, M. Green, and
R. W. Titball. 1999. An IgG1 titre to the F1 and V antigens correlates with
protection against plague in the mouse model. Clin. Exp. Immunol. 116:107–
114.
96. Yang, X., B. J. Hinnebusch, T. Trunkle, C. M. Bosio, Z. Suo, M. Tighe, A.
Harmsen, T. Becker, K. Crist, N. Walters, R. Avci, and D. W. Pascual. 2007.
Oral vaccination with Salmonella simultaneously expressing Yersinia pestis
F1 and V antigens protects against bubonic and pneumonic plague. J. Im-
munol. 178:1059–1067.
97. Yersin, A. 1895. La peste bubonique (deuxième note). Ann. Inst. Pasteur.
9:589–592.
98. Zav’yalov, V., A. Denesyuk, G. Zav’yalova, and T. Korpela. 1995. Molecular
modeling of the steric structure of the envelope F1 antigen of Yersinia pestis.
Immunol. Lett. 45:19–22.
Editor: R. P. Morrison
3650 ARLEN ET AL. INFECT. IMMUN.
 on S
eptem
ber 17, 2019 at U
N
IV
 O
F
 C
E
N
T
R
A
L F
LO
R
ID
A
http://iai.asm
.org/
D
ow
nloaded from
 
